Please use this identifier to cite or link to this item:
https://doi.org/10.1093/jac/dkx081
DC Field | Value | |
---|---|---|
dc.title | Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial | |
dc.contributor.author | Gurumurthy, Meera | |
dc.contributor.author | Verma, Rupangi | |
dc.contributor.author | Naftalin, Claire M | |
dc.contributor.author | Hee, Kim Hor | |
dc.contributor.author | Lu, Qingshu | |
dc.contributor.author | Tan, Kin Hup | |
dc.contributor.author | Issac, Simi | |
dc.contributor.author | Lin, Wenwei | |
dc.contributor.author | Tan, Angelia | |
dc.contributor.author | Seng, Kok-Yong | |
dc.contributor.author | Lee, Lawrence Soon-U | |
dc.contributor.author | Paton, Nicholas I | |
dc.date.accessioned | 2021-11-17T05:35:45Z | |
dc.date.available | 2021-11-17T05:35:45Z | |
dc.date.issued | 2017-07-01 | |
dc.identifier.citation | Gurumurthy, Meera, Verma, Rupangi, Naftalin, Claire M, Hee, Kim Hor, Lu, Qingshu, Tan, Kin Hup, Issac, Simi, Lin, Wenwei, Tan, Angelia, Seng, Kok-Yong, Lee, Lawrence Soon-U, Paton, Nicholas I (2017-07-01). Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 72 (7) : 2012-2019. ScholarBank@NUS Repository. https://doi.org/10.1093/jac/dkx081 | |
dc.identifier.issn | 03057453 | |
dc.identifier.issn | 14602091 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/206576 | |
dc.description.abstract | Background: Faropenem has in vitro activity against Mycobacterium tuberculosis (Mtb) and shows synergy with rifampicin.We tested this in a whole-blood bactericidal activity (WBA) trial. Methods: We randomized healthy volunteers to receive a single oral dose of faropenem (600 mg) with amoxicillin/ clavulanic acid (500/125 mg) (n=8), rifampicin (10 mg/kg) (n=14) or the combination rifampicin+ faropenem+amoxicillin/clavulanic acid (n=14). Blood was drawn at intervals to 8 h post-dose. Drug levels were measured using LC-tandem MS. WBA was measured by inoculating blood samples with Mtb and estimating the change in bacterial cfu after 72 h. Trial registration: ClinicalTrials.gov (NCT02393586). Results: There was no activity in the faropenem+amoxicillin/clavulanic acid group (cumulative WBA 0.02 Δlog cfu; P=0.99 versus zero change). There was a suggestion of a trend favouring the rifampicin+faropenem+amoxicillin/clavulanic acid group at 8 h (cumulative WBA -0.19±0.03 and -0.26±0.03 Δlog cfu in the rifampicin and rifampicin+faropenem+amoxicillin/clavulanic acid groups, respectively; P=0.180), which was significant in the first hour post-dose (P=0.032). Faropenem Cmax and AUC were 5.4 mg/L and 16.2mg·h/L, respectively, and MIC for Mtb H37Rv was 5-10 mg/L. Conclusions: Faropenem is not active when used alone, possibly due to inadequate plasma levels relative to MIC. However, there was a suggestion of modest synergy with rifampicin that may merit further testing in clinical trials. | |
dc.language.iso | en | |
dc.publisher | OXFORD UNIV PRESS | |
dc.source | Elements | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Infectious Diseases | |
dc.subject | Microbiology | |
dc.subject | Pharmacology & Pharmacy | |
dc.subject | CEFUROXIME AXETIL | |
dc.subject | STABILITY | |
dc.type | Article | |
dc.date.updated | 2021-11-11T06:23:15Z | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | PHARMACOLOGY | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1093/jac/dkx081 | |
dc.description.sourcetitle | JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | |
dc.description.volume | 72 | |
dc.description.issue | 7 | |
dc.description.page | 2012-2019 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Activity of faropenem with and without rifampicin against.pdf | Published version | 303.16 kB | Adobe PDF | CLOSED | None |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.